Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

GOLDENWELL BIOTECH, INC.

CIK 1800373 GWLL·Manufacturing · All EDGAR filings ↗

Progression

  1. Late filing NT 10-K
  2. Restatement 8-K +57d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Restatement SEC item code

GOLDENWELL BIOTECH, INC. said previously issued financial statements should no longer be relied upon

Item 4.02(a) — management or the board reached the conclusion

Evidence
Item code
4.02
Item title
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
Limb
a
Limb basis
explicit item reference
Limb label
Item 4.02(a) — management or the board reached the conclusion
Severity
normal
Source
SEC 8-K item code
Why
The company told investors that previously issued financial statements should no longer be relied upon.

Source filing ↗

Late filing elevated Filing comparison

GOLDENWELL BIOTECH, INC. told the SEC it could not file its quarterly report on time

Does not expect a significant change in results. Filed 3 days before the statutory due date. other reports also outstanding

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. The Registrant expects to file the Quarterly Report on or before May 19, 2026.
Evidence
Anticipates significant change
No
Days past due date
-3
Other periodic reports filed
No
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026. The Registrant expects to file the Quarterly Report on or before May 19, 2026.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗

Late filing elevated Filing comparison

GOLDENWELL BIOTECH, INC. told the SEC it could not file its annual report on time

Does not expect a significant change in results. Filed on the statutory due date.

The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Registrant expects to file the Annual Report on or before April 15, 2026.
Evidence
Anticipates significant change
No
Days past due date
0
Other periodic reports filed
Yes
Routine
No
Severity
elevated
Source
Form 12b-25 (notification of late filing)
Stated reason
The Registrant has been unable, without unreasonable effort or expense, to timely compile all information for the financial statements and related disclosures required to be included in its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Registrant expects to file the Annual Report on or before April 15, 2026.
Why
The company told the SEC it could not file a periodic report on time, using Form 12b-25.

Source filing ↗